Skip to content
DataLookout
Menu

ADMIRENCT06456554

Acellular Dermal Matrix Investigation in Breast Reconstruction

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 17 versions: 17 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 2026 to Dec 2027
    • Eligibility criteria expanded, about 21 words
    • Site details revised at 2 of 13 sites
  2. Minor Trial sites expanded: 10 → 13 locationsv16
  3. Minor Study sites revised (10)v15
  4. Notable Eligibility criteria shortened, about 7 words
    • Study sites revised (10)
    v14
  5. Minor Study sites: 7 to 10v13
Show 11 earlier versionsHide 11 earlier versions
  1. Minor Study sites: 6 to 7v12
  2. Minor Study sites: 4 to 6v11
  3. Minor Study sites: 3 to 4v10
  4. Notable Eligibility criteria expanded, about 2 words
    • Collaborators: 2 to 1
    v9
  5. Minor Start date changed from estimate of Oct 2024 to Nov 22, 2024v8
  6. Minor Site details revised at 1 of 3 sitesv7
  7. Minor Study sites: 2 to 3v6
  8. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date: Sep 2024 to Oct 2024
    v5
  9. Minor Study sites: 0 to 1v4
  10. Minor Start date: Aug 2024 to Sep 2024v3
  11. Notable Phase: Phase 3 to Not applicablev2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Rate of major adverse events
Timeframe: 12 months
Health related quality of life
Timeframe: 12 months

Secondary (4)

Change in quality of life
Procedure related adverse events
Investigational device related adverse events
Histopathology assessment

Arms and interventions

Acellular Dermal MatrixExperimental

Breast reconstruction with Cortiva Tissue Matrix

no Acellular Dermal MatrixNo intervention

Breast reconstruction only with no ADM

Devices: Acellular Dermal Matrix (Cortiva Tissue Matrix)

Sites

13 sites in 1 country